These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30196990)

  • 21. Interstitial nephritis in immune checkpoint inhibitor therapy.
    Manohar S; Albright RC
    Kidney Int; 2019 Jul; 96(1):252. PubMed ID: 31229042
    [No Abstract]   [Full Text] [Related]  

  • 22. Takotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Ederhy S; Cautela J; Ancedy Y; Escudier M; Thuny F; Cohen A
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1187-1190. PubMed ID: 29550317
    [No Abstract]   [Full Text] [Related]  

  • 23. Acute cerebellitis after administration of nivolumab and ipilimumab for small cell lung cancer.
    Naito T; Osaki M; Ubano M; Kanzaki M; Uesaka Y
    Neurol Sci; 2018 Oct; 39(10):1791-1793. PubMed ID: 29948463
    [No Abstract]   [Full Text] [Related]  

  • 24. Nivolumab plus ipilimumab in metastatic colorectal cancer.
    Gourd E
    Lancet Oncol; 2018 Mar; 19(3):e139. PubMed ID: 29395861
    [No Abstract]   [Full Text] [Related]  

  • 25. The Mayo Clinic Experience With the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab.
    Ruff MW; Mauermann ML
    Neurologist; 2018 May; 23(3):98-99. PubMed ID: 29722744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal effects of immune checkpoint inhibitors.
    Izzedine H; Mateus C; Boutros C; Robert C; Rouvier P; Amoura Z; Mathian A
    Nephrol Dial Transplant; 2017 Jun; 32(6):936-942. PubMed ID: 28025384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Severe ipilimumab-induced ulcerative colitis remitting after infliximab therapy and secondary switching with pembrolizumab].
    Yelehe-Okouma M; Granel-Brocard F; Hudziak H; Schmutz JL; Gillet P
    Therapie; 2018; 73(3):291-293. PubMed ID: 29203065
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
    Ali AK; Watson DE
    Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma.
    Sakaguchi C; Yano S; Ashida K; Wada N; Ohe K; Nagata H; Matsuda Y; Sakamoto S; Sakamoto R; Ohnaka K; Uchi H; Furue M; Nomura M; Ogawa Y
    Am J Case Rep; 2019 Jan; 20():106-110. PubMed ID: 30679413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ipilimumab- and nivolumab-associated enterocolitis with florid necrotising granulomatous inflammation: a novel manifestation of 'immunomodulatory' enterocolitis.
    Paton DJW; Warburton L; Chung K; Meniawy TM; Kumarasinghe MP
    Pathology; 2018 Jun; 50(4):466-469. PubMed ID: 29735170
    [No Abstract]   [Full Text] [Related]  

  • 31. Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events.
    Albayda J; Bingham CO; Shah AA; Kelly RJ; Cappelli L
    Rheumatology (Oxford); 2018 Apr; 57(4):760-762. PubMed ID: 29342300
    [No Abstract]   [Full Text] [Related]  

  • 32. Acute visual loss after ipilimumab treatment for metastatic melanoma.
    Wilson MA; Guld K; Galetta S; Walsh RD; Kharlip J; Tamhankar M; McGettigan S; Schuchter LM; Fecher LA
    J Immunother Cancer; 2016; 4():66. PubMed ID: 27777775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors.
    Arangalage D; Delyon J; Lermuzeaux M; Ekpe K; Ederhy S; Pages C; Lebbé C
    Ann Intern Med; 2017 Nov; 167(9):683-684. PubMed ID: 28869988
    [No Abstract]   [Full Text] [Related]  

  • 34. Macrophage activation syndrome: A new complication of checkpoint inhibitors.
    Malissen N; Lacotte J; Du-Thanh A; Gaudy-Marqueste C; Guillot B; Grob JJ
    Eur J Cancer; 2017 May; 77():88-89. PubMed ID: 28365531
    [No Abstract]   [Full Text] [Related]  

  • 35. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
    Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
    J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients.
    Shirali AC; Perazella MA; Gettinger S
    Am J Kidney Dis; 2016 Aug; 68(2):287-291. PubMed ID: 27113507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe polyradiculoneuritis associated with the combination of ipilimumab and pembrolizumab in a lung cancer patient.
    Cho HS; Lee KY; Hu CJ; Chung CC
    Neurol India; 2018; 66(2):509-511. PubMed ID: 29547174
    [No Abstract]   [Full Text] [Related]  

  • 38. Ipilimumab granulomatous interstitial nephritis.
    Thajudeen B; Madhrira M; Bracamonte E; Cranmer LD
    Am J Ther; 2015; 22(3):e84-7. PubMed ID: 24067875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review.
    Supakornnumporn S; Katirji B
    J Clin Neuromuscul Dis; 2017 Dec; 19(2):80-83. PubMed ID: 29189553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
    Gupta A; Shah U; Khine H; Vandergriff T; Froehlich T
    Melanoma Res; 2017 Apr; 27(2):171-173. PubMed ID: 28099367
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.